For secondary outcomes, the total number of patients with reduced and normal albumin levels who experienced cardiovascular events were respectively: 22 555 and 8629 all-cause death (HR, 2.77 [95% CI, 2.70–2.84]), 23 147 and 18 480 heart failure (HR, 1.31 [95% CI, 1.29–1.34]), 26 202 and 24 382 atrial fibrillation (HR, 1.11 [95% CI, 1.09–1.13]), 3145 and 2223 severe ventricular arrhythmias (HR, 1.38 [95% CI, 1.30–1.46]), 8403 and 5460 myocardial infarction (HR, 1.60 [95% CI, 1.54–1.65]), and 289 and 197 Takotsubo cardiomyopathy (HR, 1.51 [95% CI, 1.26–1.82]; Table 2). This evidence concerns the gene ALB and atrial fibrillation.